August 2008 Oncology News International

News
Article

Cover Story

  • High cost of biologics takes a toll on hem/onc practices
  • FDA cracks down on counterfeit cancer cure products

DEPARTMENTS

Focus on Breast Cancer

  • Mastectomy rates for early breast cancer are on the upswing at one Mayo Clinic
  • Is breast MRI primed for widespread use as a high-risk screening tool?
  • Vantage Point: Risk factors will guide the imaging paradigm

Focus on Lung Cancer

  • Anti-IGF-1R antibody plus chemo active in advanced non-small-cell lung cancer

News & Analysis

  • Oncologic drug safety: Separating fact from fiction

Focus on Prostate Cancer

  • Dual antiangiogenic therapy plus chemo is active in advanced prostate cancer

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
4 experts are featured in this series.
4 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
Related Content
Site Logo

BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer

Roman Fabbricatore
November 1st 2025
Article

Among patients with locally advanced/metastatic urothelial cancer who received at least one 2.2 mg/kg dose of BL-B01D1, the confirmed ORR was 44.1%.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

AI may transform oncology with Scout, an innovative assistant enhancing clinical insights and treatment strategies for TP53-mutant MCL and multiple myeloma.

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights

Gina Mauro
November 1st 2025
Article

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Combinations of anti-angiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis

Tim Cortese
October 31st 2025
Article

Combinations of anti-angiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.

Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers

Tim Cortese
October 31st 2025
Article

A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.